Blueprint
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
February 8, 2019
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
15 Adam
Street
London, England WC2N 6LA
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
8 February
2019
DIRECTORATE CHANGES
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces, in accordance
with Listing Rule 9.6.11(2) R, that Ian Barlow will retire as
Senior Independent Director and Non-Executive Director, and Michael
Friedman will retire as Chair of the Ethics & Compliance
Committee and Non-Executive Director at the conclusion of the
Annual General Meeting (AGM) on 11 April 2019.
Roberto Quarta, Chair, said
"Ian Barlow and Michael Friedman have served Smith & Nephew for
many years, 15 collectively.We will miss their great wisdom and
experience. On behalf of the whole Board I would like to thank them
for their dedicated service and wish them well for the
future."
Following the AGM on 11 April 2019, and subject to their
re-election as Directors of Smith & Nephew plc at the AGM,
Robin Freestone will be appointed as Senior Independent
Non-Executive Director, in place of Ian Barlow and Marc Owen will
succeed Michael Friedman as Chair of the Ethics & Compliance
Committee. Additionally, Robin Freestone and Erik Engstrom will
become members of the Nomination & Governance Committee and
Virginia Bottomley and Roland Diggelmann will become members of the
Ethics & Compliance Committee.
Enquiries
|
Investors
|
|
|
Andrew SwiftSmith & Nephew
|
+44 (0) 20 7960 2285
|
|
Media
|
|
|
Charles ReynoldsSmith & Nephew
|
+44 (0) 1923 477314
|
|
|
|
|
Ben Atwell / Andrew WardFTI Consulting
|
+44 (0) 20 3727 1000
|
|
|
|
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business with
leadership positions in Orthopaedics, Advanced Wound Management and
Sports Medicine. Smith & Nephew has more than 16,000 employees
and a presence in more than 100 countries. Annual sales in 2018
were $4.9 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN). For more information about Smith & Nephew,
please visit our corporate website www.smith-nephew.com and
follow us on Twitter, LinkedIn or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered
US Patent and Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: February
8, 2019
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary